BCL2L1 and Thrombocytopenia: An oral active version, ABT263/Navitoclax, was subsequently developed, but its clinical utility is restricted due to the increased risk of thrombocytopenia as a consequence of its BCL(X)L inhibiting activity31, an important protein for platelet survival.